Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Biktarvy in HIV-Positive Renal Transplant Recipients
NCT04530630Phase 4Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Weill Cornell Medicine. Started Nov 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04530630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530630.